Initial SaaS implementation
Define the supplier and service, approved intended use, GxP assessment, customer configuration, interfaces, migrated data, access and roles, electronic records and signatures, and shared-responsibility boundary. The initial validation package should cover supplier assessment, requirements, configuration specification, functional risk assessment, migration and interface plans, testing, deviations, validation summary, release readiness, and operational ownership.
Routine supplier releases
For every release, review authoritative release notes, known issues, supplier testing, security notices, and customer configuration exposure. Map changed components to enabled GxP functions and shared dependencies. Choose one of four outcomes: no relevant impact, documentation or monitoring only, targeted confirmation, or broader regression and formal escalation.
Major supplier changes
Treat architecture, authentication or identity, application programming interface (API), data model, major workflow, hosting, sub-processor, and material data-location changes as assessment prompts—not automatic risk conclusions. Determine whether the approved use, records, control effectiveness, availability, recovery, privacy, or previously demonstrated performance can change.
Recurring fictional eQMS example
A weekly eQMS release contains a cosmetic dashboard change, a workflow-engine defect correction, and a signed-PDF export update. The customer accepts supplier regression for the unchanged standard platform. A brief usability check covers the dashboard. Configured CAPA branches, legacy open records, unauthorized transitions, signer identity, signature meaning, record revision, and accurate copy are tested locally. The release is approved only after a legacy blank-value routing deviation and missing signature meaning are corrected.
Maintaining the validated state
| Operational evidence | What the review should establish |
|---|---|
| Incidents and problems | Whether actual failures challenge prior risk assumptions or controls |
| Change control and releases | Whether cumulative changes remain within the approved use and evidence boundary |
| Supplier performance | Notification quality, defect handling, service levels, and unresolved commitments |
| User access review | Continued appropriateness of business, Quality, support, and privileged roles |
| Backup and restore | Supplier and customer responsibilities and demonstrated record retrieval |
| Business continuity | Dependencies, recovery objectives, workarounds, reconciliation, and return to service |
| Periodic review | Evidence-based conclusion that current use remains supported |
Regulatory and procedural context
Primary sources. FDA CSA guidance ↗ discusses risk-based assurance and the use of supplier evidence. EU GMP Annex 11 ↗ addresses lifecycle risk management and supplier/service-provider responsibilities for applicable GMP systems.
Company procedure. The organization’s approved validation, change-control, supplier-management, information-security, data-integrity, records-retention, and Quality approval procedures determine the required records, roles, and approval route.
CSVtoCSA practitioner interpretation. Continuous delivery needs continuous impact assessment, not automatic repetition of the historical protocol or automatic acceptance of the supplier’s label. This is a recommended validation approach, not a statement that every listed activity is a direct regulatory requirement.